desferrioxamine - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	desferrioxamine	go back to main search page
Accession:	CHEBI:50453	browse the term

show annotations for term's descendants Sort by:
Rat (268) Mouse (266) Human (268) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (268)

desferrioxamine B

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

increases activity
multiple interactions
increases expression

Deferoxamine results in increased activity of ACO1 protein
[Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein
Deferoxamine results in increased expression of ACO1 protein

PMID:10397746 PMID:11054110 PMID:15893546 PMID:16568477 PMID:18073202 More...

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

aconitase 2

decreases expression

Deferoxamine results in decreased expression of ACO2 protein

PMID:16568477 PMID:17469137

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acid phosphatase 5, tartrate resistant

decreases activity
multiple interactions

Deferoxamine results in decreased activity of ACP5 protein
Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions
increases expression

Deferoxamine results in decreased expression of ACTA2 protein
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA]
Deferoxamine results in increased expression of ACTA2 mRNA

PMID:18032466 PMID:30551460

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adrenomedullin

increases expression

Deferoxamine results in increased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

AKT serine/threonine kinase 1

multiple interactions

Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]

PMID:18032466 PMID:34577062 PMID:35690295

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 3 family, member A1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of ALDH3A1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

alkaline phosphatase, biomineralization associated

decreases expression
multiple interactions

Deferoxamine results in decreased expression of ALPL mRNA
Deferoxamine results in decreased expression of ALPL protein
Indomethacin promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]; Sulindac promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]

PMID:16772336 PMID:21882223

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

annexin A3

multiple interactions
decreases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein]
Deferoxamine results in decreased expression of ANXA3 protein

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

apoptotic peptidase activating factor 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]

PMID:33962019 PMID:35690295

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein

affects binding
multiple interactions

Deferoxamine binds to APP 5' UTR
[Deferoxamine binds to APP 5' UTR] which results in decreased expression of APP protein; [Deferoxamine binds to APP 5' UTR] which results in decreased secretion of APP protein modified form; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]

PMID:15681799 PMID:17964426

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 4

multiple interactions

Deferoxamine inhibits the reaction [manganese(III) acetate dihydrate results in increased expression of AQP4 protein]

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

Rho GDP dissociation inhibitor alpha

decreases expression
multiple interactions

Deferoxamine results in decreased expression of ARHGDIA protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

aryl hydrocarbon receptor nuclear translocator

increases activity
increases expression
multiple interactions

Deferoxamine results in increased activity of ARNT protein
Deferoxamine results in increased expression of ARNT mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]

PMID:10559391 PMID:33962019 PMID:35690295

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

ASH2 like histone lysine methyltransferase complex subunit

increases expression
affects expression

Deferoxamine results in increased expression of ASH2L mRNA
Deferoxamine affects the expression of ASH2L mRNA

NCBI chr16:66,242,205...66,264,064
Ensembl chr16:66,242,212...66,264,061

G

activating transcription factor 1

increases activity

Deferoxamine results in increased activity of ATF1 protein

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

ATM serine/threonine kinase

multiple interactions

Deferoxamine results in increased phosphorylation of and results in increased activity of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase H+ transporting V0 subunit D2

multiple interactions
affects expression

Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase copper transporting alpha

increases expression
multiple interactions

Deferoxamine results in increased expression of ATP7A mRNA
cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein]

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

BCL2-antagonist/killer 1

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA]

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Deferoxamine results in increased expression of BAX mRNA; Deferoxamine results in increased expression of BAX protein
[Cisplatin co-treated with Deferoxamine] results in increased expression of BAX protein; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BAX mRNA]

PMID:16800926 PMID:21742779 PMID:33962019 PMID:34126102 PMID:34577062 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression
multiple interactions

Deferoxamine results in increased expression of BBC3 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased expression of BCL2 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]
Deferoxamine results in decreased expression of BCL2 mRNA

PMID:30431687 PMID:33962019 PMID:34577062 PMID:35690295

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 15

increases expression
multiple interactions

Deferoxamine results in increased expression of BCL2L15 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]

NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078

G

brain-derived neurotrophic factor

multiple interactions

Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

multiple interactions

Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of BECN1 protein]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BECN1 protein]

PMID:21742779 PMID:32687844

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

bone morphogenetic protein 6

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine results in decreased expression of BMP6 mRNA

PMID:25633564 PMID:32816093

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

BCL2 interacting protein 3

increases expression
multiple interactions

Deferoxamine results in increased expression of BNIP3 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

increases expression
multiple interactions

Deferoxamine results in increased expression of BNIP3L mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]

PMID:11832486 PMID:33962019

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

complement C5

multiple interactions

Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of C5 protein]; Deferoxamine inhibits the reaction [Asbestos, Serpentine results in increased cleavage of C5 protein]

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

calcium voltage-gated channel subunit alpha1 H

increases expression

Deferoxamine results in increased expression of CACNA1H mRNA

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

carbonic anhydrase 2

decreases expression

Deferoxamine results in decreased expression of CAR2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

carbonic anhydrase 9

increases expression

Deferoxamine results in increased expression of CA9 mRNA

NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838

G

caspase 12

multiple interactions

Deferoxamine promotes the reaction [manganese chloride results in increased cleavage of and results in increased activity of CASP12 protein]

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

increases expression
multiple interactions
increases activity

Deferoxamine results in increased expression of CASP3 protein
Deferoxamine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Deferoxamine inhibits the reaction [Manganese results in increased activity of CASP3 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Deferoxamine promotes the reaction [manganese chloride results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]
Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]

PMID:11933051 PMID:12523938 PMID:16374551 PMID:16800926 PMID:23764342 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity
multiple interactions

Deferoxamine results in increased activity of CASP8 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]

PMID:16374551 PMID:33962019 PMID:35690295

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased activity of CASP9 protein]

PMID:12540492 PMID:14766669

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased activity of CAT protein]; Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CAT mRNA

PMID:22115772 PMID:34577062 PMID:35690295

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

increases expression

Deferoxamine results in increased expression of CAV1 protein

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

C-C motif chemokine ligand 2

multiple interactions

Deferoxamine inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin A2

decreases expression

Deferoxamine results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Deferoxamine results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

Deferoxamine results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

decreases expression

Deferoxamine results in decreased expression of CCND2 protein

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

decreases expression

Deferoxamine results in decreased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

increases expression

Deferoxamine results in increased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

CD36 molecule

decreases expression

Deferoxamine results in decreased expression of CD36 protein

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14A

increases expression

Deferoxamine results in increased expression of CDC14A mRNA alternative form

NCBI chr 2:204,225,540...204,380,927
Ensembl chr 2:204,225,540...204,380,927

G

cyclin dependent kinase 2

decreases activity
decreases expression

Deferoxamine results in decreased activity of CDK2 protein
Deferoxamine results in decreased expression of CDK2 protein

PMID:11468187 PMID:17631934

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
decreases expression
multiple interactions

Deferoxamine results in increased expression of CDKN1A mRNA; Deferoxamine results in increased expression of CDKN1A protein
Deferoxamine results in decreased expression of CDKN1A protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]

PMID:10397746 PMID:10559391 PMID:11468187 PMID:12807743 PMID:16227210 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1B mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA]

PMID:33962019 PMID:35690295

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

creatine kinase B

multiple interactions

[Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Acetaminophen results in decreased activity of CKB protein]; [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CKB protein]

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

collagen type I alpha 1 chain

multiple interactions

Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cytochrome c oxidase subunit 4i1

multiple interactions

Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

ceruloplasmin

multiple interactions

Deferoxamine inhibits the reaction [CP protein results in increased oxidation of 3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxyl]

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 1

increases activity

Deferoxamine results in increased activity of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

C-reactive protein

multiple interactions

Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CRP protein]

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 2

multiple interactions

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA]

PMID:20801209 PMID:21703343

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

catenin beta 1

multiple interactions

[Oxygen deficiency co-treated with Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] affects the localization of CTNNB1 protein; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of CTNNB1 protein]

PMID:20338187 PMID:34648812

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin K

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

C-X-C motif chemokine ligand 2

multiple interactions

Deferoxamine promotes the reaction [Asbestos, Amphibole results in increased expression of CXCL2]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome b-245 beta chain

multiple interactions

[Deferoxamine co-treated with Benzene] results in increased expression of CYBB protein; Deferoxamine inhibits the reaction [Benzene results in increased expression of CYBB mRNA]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome c, somatic

multiple interactions
increases expression

[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA]
Deferoxamine results in increased expression of CYCS mRNA

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]
Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]

PMID:10799651 PMID:10823667 PMID:20801209 PMID:21703343

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Deferoxamine inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression

Deferoxamine results in decreased expression of CYP3A4 mRNA; Deferoxamine results in decreased expression of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

multiple interactions

Deferoxamine promotes the reaction [manganese chloride results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

desmin

multiple interactions
increases expression

Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA]
Deferoxamine results in increased expression of DES mRNA

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

diablo, IAP-binding mitochondrial protein

increases expression
multiple interactions

Deferoxamine results in increased expression of DIABLO mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA]

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

dicer 1 ribonuclease III

decreases expression

Deferoxamine results in decreased expression of DICER1 mRNA; Deferoxamine results in decreased expression of DICER1 protein

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

iodothyronine deiodinase 2

increases activity

Deferoxamine results in increased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

dynamin 1-like

multiple interactions

Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]

PMID:26318285 PMID:33962019

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

DNA methyltransferase 1

increases expression
decreases expression

Deferoxamine results in increased expression of DNMT1 mRNA
Deferoxamine results in decreased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 alpha

decreases expression
increases expression

Deferoxamine results in decreased expression of DNMT3A mRNA
Deferoxamine results in increased expression of DNMT3A mRNA

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

DNA methyltransferase 3 beta

decreases expression
increases expression

Deferoxamine results in decreased expression of DNMT3B mRNA
Deferoxamine results in increased expression of DNMT3B mRNA

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

dual oxidase 1

multiple interactions

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX1 mRNA]

NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563

G

dual oxidase 2

multiple interactions

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX2 mRNA]

NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902

G

dual specificity phosphatase 1

increases expression

Deferoxamine results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

endothelin 1

increases expression

Deferoxamine results in increased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor receptor

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]

PMID:15626777 PMID:35690295

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

egl-9 family hypoxia-inducible factor 1

decreases expression

Deferoxamine results in decreased expression of EGLN1 protein

NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777

G

euchromatic histone lysine methyltransferase 2

decreases expression

Deferoxamine results in decreased expression of EHMT2 mRNA

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

elastase, neutrophil expressed

multiple interactions

Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA]

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

enolase 1

increases expression

Deferoxamine results in increased expression of ENO1 mRNA

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

endothelial PAS domain protein 1

multiple interactions
increases stability
increases expression

Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein]
Deferoxamine results in increased stability of EPAS1 protein
Deferoxamine results in increased expression of EPAS1 protein

PMID:18353899 PMID:18515279 PMID:21558026 PMID:22447124 PMID:26735578 More...

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erythropoietin

increases expression
multiple interactions
increases stability

Deferoxamine results in increased expression of EPO mRNA
Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]
Deferoxamine results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO protein
Deferoxamine deficiency results in increased stability of EPO mRNA
Deferoxamine deficiency results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO mRNA

PMID:9927288 PMID:10559391 PMID:10699462 PMID:10756076 PMID:21558026

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

Deferoxamine promotes the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

endoplasmic reticulum oxidoreductase 1 alpha

increases expression

Deferoxamine results in increased expression of ERO1A mRNA

NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478

G

endoplasmic reticulum protein 29

decreases expression
multiple interactions

Deferoxamine results in decreased expression of ERP29 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]

NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376

G

exonuclease 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

coagulation factor III, tissue factor

multiple interactions

Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid binding protein 4

decreases expression

Deferoxamine results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid synthase

multiple interactions

[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

ferrochelatase

decreases expression
multiple interactions

Deferoxamine results in decreased expression of FECH protein
ferric chloride inhibits the reaction [Deferoxamine results in decreased expression of FECH protein]

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

G

fission, mitochondrial 1

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA]

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

fibronectin 1

multiple interactions

Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

ferritin heavy chain 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of FTH1 protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in decreased expression of FTH1 protein]
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [Iron-Dextran Complex results in increased expression of FTH1 protein]

PMID:15893546 PMID:16568477 PMID:16777245 PMID:17469137 PMID:32687844 More...

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions
decreases expression

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]
Deferoxamine results in decreased expression of FTL1 protein
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTL1 protein]

PMID:12393473 PMID:12644586 PMID:15893546 PMID:16568477 PMID:35661779

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

ferritin mitochondrial

multiple interactions

Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]

NCBI chr18:45,758,874...45,760,123
Ensembl chr18:45,758,874...45,760,123

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Deferoxamine results in increased expression of GADD45A mRNA

PMID:10397746 PMID:11468187

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression
multiple interactions

Deferoxamine results in decreased expression of GAPDH protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

growth arrest-specific 1

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA

NCBI chr17:4,482,168...4,485,153

G

1,4-alpha-glucan branching enzyme 1

increases expression

Deferoxamine results in increased expression of GBE1 mRNA

NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210

G

glucokinase

affects expression

Deferoxamine affects the expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

Deferoxamine inhibits the reaction [Benzene results in decreased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glyoxalase 1

increases expression
multiple interactions

Deferoxamine results in increased expression of GLO1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

golgi SNAP receptor complex member 1

multiple interactions

GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]

NCBI chr10:61,570,499...61,607,287
Ensembl chr10:61,450,494...61,607,177
Ensembl chr10:61,450,494...61,607,177

G

glutathione peroxidase 4

multiple interactions

Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 protein]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein]
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]

PMID:32416107 PMID:35661779 PMID:36843388

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glycogen synthase kinase 3 beta

multiple interactions
decreases phosphorylation

Deferoxamine inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein]
Deferoxamine results in decreased phosphorylation of GSK3B protein
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of GSK3B protein]

PMID:25246272 PMID:34577062

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hepcidin antimicrobial peptide

multiple interactions
affects expression
decreases expression

Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine affects the expression of HAMP mRNA
Deferoxamine results in decreased expression of HAMP protein

PMID:21558026 PMID:25633564

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

hepatitis A virus cellular receptor 1

multiple interactions

Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
affects localization
decreases degradation
increases activity
increases stability
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Doxorubicin co-treated with Deferoxamine] results in increased expression of HIF1A protein; [Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA; [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Arsenic Trioxide promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; Cadmium inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A protein]]; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Deferoxamine results in increased expression of and results in increased stability of HIF1A protein; Deferoxamine results in increased stability of and results in increased expression of HIF1A protein; dihydrotanshinone I inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine affects the localization of HIF1A protein
Deferoxamine results in decreased degradation of HIF1A protein
[Deferoxamine results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine results in increased stability of HIF1A protein
Deferoxamine results in increased expression of HIF1A mRNA; Deferoxamine results in increased expression of HIF1A protein

PMID:10559391 PMID:10866824 PMID:11286986 PMID:12393473 PMID:14604972 More...

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hypoxia inducible factor 3 subunit alpha

increases expression

Deferoxamine results in increased expression of HIF3A protein

NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758

G

hexokinase 2

increases expression
multiple interactions

Deferoxamine results in increased expression of HK2 protein
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 protein]]; Doxorubicin inhibits the reaction [Deferoxamine results in increased expression of HK2 protein]

PMID:34126102 PMID:36116563

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

heme oxygenase 1

multiple interactions
decreases expression
decreases degradation

Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]
Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; Deferoxamine inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]
Deferoxamine results in decreased expression of HMOX1 mRNA
Deferoxamine results in decreased degradation of HMOX1 protein

PMID:9747510 PMID:10814519 PMID:12393473 PMID:16439612 PMID:18073186 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 1A

multiple interactions
decreases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein]
Deferoxamine results in decreased expression of HSPA1A protein

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]

NCBI chr13:83,273,176...83,274,317

G

heat shock protein family A (Hsp70) member 9

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

heat shock protein family D (Hsp60) member 1

multiple interactions
decreases expression

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA; ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]
Deferoxamine results in decreased expression of HSPD1 protein

PMID:19515424 PMID:24170104 PMID:35690295

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

heat shock protein family H (Hsp110) member 1

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

intercellular adhesion molecule 1

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

multiple interactions

Deferoxamine inhibits the reaction [Copper Sulfate results in decreased secretion of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

multiple interactions

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression
increases expression

Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; ferric chloride inhibits the reaction [Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]
Deferoxamine results in decreased expression of IL1B mRNA
Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]
Deferoxamine results in increased expression of IL1B mRNA

PMID:9851740 PMID:18403674 PMID:20801209 PMID:32816093

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

multiple interactions

Deferoxamine inhibits the reaction [Mercuric Chloride results in increased expression of IL4 mRNA]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

Deferoxamine inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein]; Deferoxamine inhibits the reaction [Coal Ash results in increased expression of IL6 protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of IL6 protein]; Deferoxamine inhibits the reaction [Asbestos, Amphibole results in increased expression of IL6 mRNA]

PMID:9344885 PMID:22168577 PMID:24296301 PMID:34577062

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

increases secretion

Deferoxamine results in increased secretion of INS1 protein

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

iron responsive element binding protein 2

increases expression
multiple interactions
increases activity

Deferoxamine results in increased expression of IREB2 protein
Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]; Deferoxamine results in increased expression of and results in increased activity of IREB2 protein
Deferoxamine results in increased activity of IREB2 protein

PMID:10397746 PMID:11054110 PMID:16135072 PMID:16568477 PMID:17469137 More...

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

integrin subunit beta 3

decreases expression
multiple interactions

Deferoxamine results in decreased expression of ITGB3 mRNA
Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lysine demethylase 1A

multiple interactions

Deferoxamine results in decreased expression of and results in decreased activity of KDM1A protein

NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319

G

lysine demethylase 3A

increases expression

Deferoxamine results in increased expression of KDM3A protein

NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073

G

lysine demethylase 4A

multiple interactions

Deferoxamine results in decreased expression of and results in decreased activity of KDM4A protein

NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501

G

kinase insert domain receptor

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

lipocalin 2

multiple interactions
increases expression

Deferoxamine affects the reaction [Magnetite Nanoparticles results in increased expression of LCN2 mRNA]; Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased expression of LCN2 mRNA

PMID:17114340 PMID:23086747

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lactate dehydrogenase A

increases expression
multiple interactions

Deferoxamine results in increased expression of LDHA mRNA
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA protein]]

PMID:34998824 PMID:36116563

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin

increases expression
increases secretion

Deferoxamine results in increased expression of LEP mRNA
Deferoxamine results in increased secretion of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase E, hormone sensitive type

decreases expression

Deferoxamine results in decreased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lysyl oxidase

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

microtubule-associated protein 1 light chain 3 alpha

multiple interactions

Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of MAP1LC3A protein]

NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Deferoxamine results in increased expression of MAP1LC3B protein
Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]

PMID:25301941 PMID:32687844

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAP3K5 protein]

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK1 protein]
Deferoxamine results in increased phosphorylation of MAPK1 protein
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]

PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK3 protein]
Deferoxamine results in increased phosphorylation of MAPK3 protein
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]

PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

Deferoxamine results in increased phosphorylation of MAPK8 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]

PMID:20206247 PMID:20368581

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases phosphorylation
multiple interactions

Deferoxamine results in increased phosphorylation of MAPK9 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]

PMID:20206247 PMID:20368581

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
increases cleavage

Nitroprusside inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

mitochondrial fission factor

increases expression
multiple interactions

Deferoxamine results in increased expression of MFF mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA]

NCBI chr 9:84,007,798...84,036,039
Ensembl chr 9:84,007,798...84,036,039

G

mitofusin 2

multiple interactions

[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA; Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

mitochondrial elongation factor 2

multiple interactions
increases expression

[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA]
Deferoxamine results in increased expression of MIEF2 mRNA

NCBI chr10:45,408,055...45,414,144
Ensembl chr10:45,408,082...45,414,144

G

microRNA 155

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 184

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR184 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA]

NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210

G

microRNA 210

increases expression
increases expression

Deferoxamine results in increased expression of MIR210 mRNA
desferrioxamine B increases expression of MIR210 miRNA in trophoblast cells

CTD
RGD

PMID:24577088 PMID:22840297

NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454

G

mutL homolog 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

matrix metallopeptidase 1

multiple interactions

[Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]

PMID:10464329 PMID:19136476

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 2

multiple interactions
decreases activity

Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of MMP2 protein]; ferric chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]

PMID:10086886 PMID:20338187

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]
Deferoxamine results in decreased expression of MMP9 mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]

PMID:31238089 PMID:35690295

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mitochondrial ribosomal protein S9

multiple interactions
increases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein]

NCBI chr 9:45,113,554...45,172,375
Ensembl chr 9:45,113,554...45,172,375

G

macrophage scavenger receptor 1

multiple interactions

Deferoxamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

mitochondrially encoded ATP synthase membrane subunit 6

decreases expression

Deferoxamine results in decreased expression of ATP6 mRNA

NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599

G

mitochondrially encoded ATP synthase membrane subunit 8

decreases expression

Deferoxamine results in decreased expression of ATP8 mRNA

NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
Ensembl chr MT:7,758...7,961

G

mitochondrially encoded cytochrome c oxidase I

decreases expression

Deferoxamine results in decreased expression of COX1 mRNA

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded cytochrome c oxidase II

decreases expression

Deferoxamine results in decreased expression of COX2 mRNA

NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689

G

mitochondrially encoded cytochrome c oxidase III

decreases expression

Deferoxamine results in decreased expression of COX3 mRNA

NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382

G

mitochondrially encoded cytochrome b

decreases expression

Deferoxamine results in decreased expression of CYTB mRNA

NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

decreases expression

Deferoxamine results in decreased expression of ND1 mRNA

NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2

decreases expression

Deferoxamine results in decreased expression of ND2 mRNA

NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3

decreases expression

Deferoxamine results in decreased expression of ND3 mRNA

NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
Ensembl chr MT:9,451...9,798

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4

decreases expression

Deferoxamine results in decreased expression of ND4 mRNA

NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L

decreases expression

Deferoxamine results in decreased expression of ND4L mRNA

NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5

decreases expression

Deferoxamine results in decreased expression of ND5 mRNA

NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

decreases expression

Deferoxamine results in decreased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

metallothionein 2A

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA]

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

MYC proto-oncogene, bHLH transcription factor

increases degradation
multiple interactions
decreases expression

Deferoxamine results in increased degradation of MYC protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA
Deferoxamine results in decreased expression of MYC protein

PMID:12393473 PMID:20046830 PMID:22245592

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear receptor coactivator 4

multiple interactions

Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of NCOA4 protein]; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of NCOA4 protein]

PMID:32283200 PMID:32687844 PMID:36843388

NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

N-myc downstream regulated 1

increases expression
decreases response to substance

Deferoxamine results in increased expression of NDRG1 mRNA; Deferoxamine results in increased expression of NDRG1 protein
NDRG1 protein results in decreased susceptibility to Deferoxamine

PMID:11006124 PMID:24532803

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NADH:ubiquinone oxidoreductase subunit B8

decreases expression

Deferoxamine results in decreased expression of NDUFB8 protein

NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817

G

nestin

decreases expression

Deferoxamine results in decreased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

NFE2 like bZIP transcription factor 2

multiple interactions

Deferoxamine inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]]
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]

PMID:26945724 PMID:31066958 PMID:32416107 PMID:36450496

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of NFKBIA mRNA]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions
increases expression

Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
Deferoxamine results in increased expression of NOS2 mRNA
[Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide

PMID:7532384 PMID:18073202

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of NQO1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

oxidized low density lipoprotein receptor 1

decreases expression

Deferoxamine results in decreased expression of OLR1 protein

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions
increases expression

[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA]
Deferoxamine results in increased expression of OPA1 mRNA

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

prolyl 4-hydroxylase subunit alpha 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of P4HA1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Deferoxamine results in increased cleavage of PARP1 protein
Indomethacin promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]; Sulindac promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

platelet derived growth factor subunit A

multiple interactions

Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA]

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor subunit B

multiple interactions

Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

platelet derived growth factor receptor beta

decreases expression

Deferoxamine results in decreased expression of PDGFRB protein

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

pyruvate dehydrogenase E1 subunit beta

increases expression
multiple interactions

Deferoxamine results in increased expression of PDHB protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]

NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500

G

pyruvate dehydrogenase kinase 1

increases expression

Deferoxamine results in increased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

phosphoglycerate kinase 1

multiple interactions
decreases expression
increases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein]
Deferoxamine results in decreased expression of PGK1 protein
Deferoxamine results in increased expression of PGK1 mRNA

PMID:19515424 PMID:22447124 PMID:34998824

NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

PTEN induced kinase 1

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

PLAG1 like zinc finger 2

multiple interactions

Deferoxamine results in increased expression of and affects the localization of PLAGL2 protein

NCBI chr 3:141,695,322...141,708,516
Ensembl chr 3:141,695,322...141,708,503

G

plasminogen activator, urokinase

multiple interactions

Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA]

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

perilipin 2

multiple interactions

[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression
multiple interactions

Deferoxamine results in increased expression of PMAIP1 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA]

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

peripheral myelin protein 22

multiple interactions

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

POU class 5 homeobox 1

increases expression

Deferoxamine results in increased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peptidylprolyl isomerase A

multiple interactions
decreases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein]
Deferoxamine results in decreased expression of PPIA protein

NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601

G

protein kinase C, delta

increases phosphorylation

Deferoxamine results in increased phosphorylation of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prostaglandin-endoperoxide synthase 2

increases stability
increases expression
multiple interactions

Deferoxamine results in increased stability of PTGS2 protein
Deferoxamine results in increased expression of PTGS2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Deferoxamine inhibits the reaction [Benzene results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; [Sulindac co-treated with Deferoxamine] results in increased expression of PTGS2 protein; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Indomethacin promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]
Deferoxamine results in increased expression of PTGS2 mRNA; Deferoxamine results in increased expression of PTGS2 protein

PMID:16527254 PMID:21882223 PMID:32816093 PMID:35661779 PMID:36843388

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

receptor for activated C kinase 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of RACK1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]

NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975

G

receptor activity modifying protein 2

decreases expression

Deferoxamine results in decreased expression of RAMP2 mRNA

NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829

G

RB transcriptional corepressor 1

decreases phosphorylation

Deferoxamine results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

decreases expression

Deferoxamine results in decreased expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

S-antigen visual arrestin

multiple interactions

Deferoxamine inhibits the reaction [SAG results in increased abundance of Free Radicals]

NCBI chr 9:88,467,797...88,508,821
Ensembl chr 9:88,469,376...88,508,820

G

succinate dehydrogenase complex iron sulfur subunit B

decreases expression

Deferoxamine results in decreased expression of SDHB protein

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

selectin E

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

sestrin 2

multiple interactions

Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET domain containing 1A, histone lysine methyltransferase

increases expression

Deferoxamine results in increased expression of SETD1A mRNA

NCBI chr 1:182,386,197...182,411,695
Ensembl chr 1:182,388,060...182,411,090

G

SET domain containing 2, histone lysine methyltransferase

increases expression
affects expression

Deferoxamine results in increased expression of SETD2 mRNA
Deferoxamine affects the expression of SETD2 mRNA

NCBI chr 8:110,511,808...110,597,475
Ensembl chr 8:110,511,772...110,597,489

G

sirtuin 1

increases expression

Deferoxamine results in increased expression of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 11 member 2

multiple interactions
increases expression
decreases expression

[Deferoxamine co-treated with Manganese] results in increased expression of SLC11A2; [Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]] which results in increased uptake of Copper; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 mRNA]; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [Deferoxamine results in increased expression of SLC11A2 protein] which results in increased uptake of Manganese; Deferoxamine promotes the reaction [Deferoxamine results in increased expression of SLC11A2 protein]
Deferoxamine results in decreased expression of SLC11A2 mRNA

PMID:11933051 PMID:12393473 PMID:23764342 PMID:24089420

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

solute carrier family 19 member 2

decreases expression

Deferoxamine results in decreased expression of SLC19A2 mRNA

NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 19 member 3

decreases expression

Deferoxamine results in decreased expression of SLC19A3 mRNA

NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337

G

solute carrier family 2 member 1

multiple interactions
increases expression

[Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of SLC2A1 protein; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 protein]]
Deferoxamine results in increased expression of SLC2A1 mRNA

PMID:12032628 PMID:17442736 PMID:21558026 PMID:36116563

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 4

decreases expression

Deferoxamine results in decreased expression of SLC2A4 mRNA

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 40 member 1

increases expression
multiple interactions

Deferoxamine results in increased expression of SLC40A1 protein
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]

PMID:31238089 PMID:32416107

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

solute carrier family 44, member 4

decreases expression

Deferoxamine results in decreased expression of SLC44A4 mRNA

NCBI chr20:3,903,099...3,919,215
Ensembl chr20:3,903,099...3,919,215

G

solute carrier family 6 member 2

decreases expression

Deferoxamine results in decreased expression of SLC6A2 protein

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 7 member 11

decreases expression
multiple interactions

Deferoxamine results in decreased expression of SLC7A11 mRNA
Deferoxamine inhibits the reaction [Benzene results in decreased expression of SLC7A11 mRNA]; Deferoxamine promotes the reaction [Benzene results in decreased expression of SLC7A11 protein]
Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SLC7A11 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]

PMID:32816093 PMID:35661779 PMID:36450496 PMID:36843388

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

decreases expression

Deferoxamine results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

superoxide dismutase 1

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases expression

[Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD2 mRNA; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]
Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]

PMID:10464329 PMID:16927372 PMID:19063909 PMID:35690295

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

Sp1 transcription factor

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

Sp7 transcription factor

multiple interactions

Deferoxamine inhibits the reaction [Ascorbic Acid results in increased expression of SP7 mRNA]

NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847

G

sequestosome 1

increases expression
multiple interactions

Deferoxamine results in increased expression of SQSTM1 protein
[Copper co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]

PMID:25301941 PMID:32283200

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

ST6 beta-galactoside alpha-2,6-sialyltransferase 1

multiple interactions

ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]

NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310

G

signal transducer and activator of transcription 3

multiple interactions

Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

SUV39H1 histone lysine methyltransferase

increases expression
decreases expression

Deferoxamine results in increased expression of SUV39H1 mRNA
Deferoxamine results in decreased expression of SUV39H1 mRNA

NCBI chr X:14,421,028...14,433,993
Ensembl chr X:14,421,109...14,433,982

G

SUV39H1 histone lysine methyltransferase, pseudogene 1

decreases expression
increases expression

Deferoxamine results in decreased expression of SUV39H1 mRNA
Deferoxamine results in increased expression of SUV39H1 mRNA

NCBI chr X:141,792,589...141,795,257

G

tet methylcytosine dioxygenase 2

decreases expression

Deferoxamine results in decreased expression of TET2 protein

NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534

G

transferrin

multiple interactions

Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein]

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transferrin receptor 2

decreases expression

Deferoxamine results in decreased expression of TFR2 protein

NCBI chr12:19,107,673...19,124,622
Ensembl chr12:19,107,673...19,124,591

G

transferrin receptor

increases expression
multiple interactions

Deferoxamine results in increased expression of TFRC mRNA; Deferoxamine results in increased expression of TFRC protein
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of TFRC protein
[Deferoxamine co-treated with Benzene] results in increased expression of TFRC protein; Deferoxamine affects the reaction [Magnetite Nanoparticles results in decreased expression of TFRC mRNA]; Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein]
Deferoxamine inhibits the reaction [Doxorubicin results in decreased expression of TFRC mRNA]

PMID:11054110 PMID:12393473 PMID:12807743 PMID:15993339 PMID:16039939 More...

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions

Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

increases expression

Deferoxamine results in increased expression of TH mRNA

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

toll-like receptor 4

decreases expression

Deferoxamine results in decreased expression of TLR4 protein

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions
decreases activity
decreases expression
increases response to substance

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNF mRNA; Deferoxamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]
Deferoxamine results in decreased expression of TNF mRNA
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TNF protein]; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
Deferoxamine results in increased susceptibility to TNF protein

PMID:7532384 PMID:7539275 PMID:9851740 PMID:10486238 PMID:12633744 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

decreases expression

Deferoxamine results in decreased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF receptor superfamily member 11A

decreases expression

Deferoxamine results in decreased expression of TNFRSF11A mRNA

NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695

G

TNF superfamily member 10

multiple interactions

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions

[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53

multiple interactions
decreases response to substance
increases expression

[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
TP53 protein results in decreased susceptibility to Deferoxamine
Deferoxamine results in increased expression of TP53 protein
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TP53 mRNA]

PMID:10942736 PMID:16357363 PMID:16527254 PMID:23483119 PMID:33962019 More...

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TPD52 like 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of TPD52L1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

triosephosphate isomerase 1

increases expression

Deferoxamine results in increased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

TNF receptor-associated protein 1

decreases expression
multiple interactions

Deferoxamine results in decreased expression of TRAP1 mRNA; Deferoxamine results in decreased expression of TRAP1 protein
TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]

NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981

G

tubulin, beta 3 class III

increases expression

Deferoxamine results in increased expression of TUBB3 mRNA

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

uncoupling protein 2

decreases expression

Deferoxamine results in decreased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

vascular cell adhesion molecule 1

multiple interactions

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]

PMID:12633744 PMID:30431687

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

voltage-dependent anion channel 2

multiple interactions
decreases expression

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein]
Deferoxamine results in decreased expression of VDAC2 protein

NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553

G

vitamin D receptor

increases expression

Deferoxamine results in increased expression of VDR mRNA

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions
increases secretion
increases expression

Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased secretion of VEGFA protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Potassium Dichromate results in increased expression of VEGFA protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA]
Deferoxamine results in increased expression of VEGFA mRNA; Deferoxamine results in increased expression of VEGFA protein

PMID:10613739 PMID:12213806 PMID:15075239 PMID:16227210 PMID:17114340 More...

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

von Hippel-Lindau tumor suppressor

multiple interactions

VHL protein mutant form affects the reaction [Deferoxamine results in decreased susceptibility to Hydrogen Peroxide]

NCBI chr 4:146,772,483...146,779,376
Ensembl chr 4:146,772,468...146,779,377

G

WT1 transcription factor

multiple interactions

[cobaltous chloride co-treated with Deferoxamine] results in increased expression of WT1 mRNA

NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643

G

X-box binding protein 1

multiple interactions

Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of XBP1 protein]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19831
chemical entity	19829
atom	19829
nonmetal atom	19767
nitrogen atom	18955
nitrogen molecular entity	18955
organonitrogen compound	18804
carboxamide	17549
hydroxamic acid	6330
desferrioxamine	268
acyclic desferrioxamine +	268
cyclic desferrioxamine +	0
Path 2
Term	Annotations
CHEBI ontology	19831
subatomic particle	19829
composite particle	19829
hadron	19829
baryon	19829
nucleon	19829
atomic nucleus	19829
atom	19829
main group element atom	19779
p-block element atom	19779
carbon group element atom	19728
carbon atom	19724
organic molecular entity	19724
heteroorganic entity	19477
organochalcogen compound	19240
organooxygen compound	19155
carbon oxoacid	18613
carboxylic acid	18610
carboacyl group	17699
univalent carboacyl group	17699
carbamoyl group	17549
carboxamide	17549
hydroxamic acid	6330
desferrioxamine	268
acyclic desferrioxamine +	268
cyclic desferrioxamine +	0

paths to the root